metalloproteinase in cells that express said mammalian Cadherin-1 1 protein in one or more joints of said subject.

53. The antibody of claim 41, wherein the antibody inhibits induction of expression or activity of a cytokine or growth factor selected from the group consisting of a IL-6, IL-8, RANKL and TRANCE in cells that express said mammalian Cadherin-1 1 protein in one or more joints of said subject.

54. The antibody of Claim 41, for use in the treatment of a Caherin-11-mediated disorder in a mammalian subject, wherein the antibody is administered to said subject in combination with at least one agent selected from the group consisting of a disease-modifying anti-rheumatic drug and an anti-inflammatory agent.

55. Use of a humanized antibody for the treatment of a Cadherin-11-mediated disorder in a mammalian subject in need thereof, wherein the antibody specifically binds an EC1 domain of a mammalian Cadherin-11 protein and comprises an antibody variable heavy chain region comprising SEQ ID NO:69 and an antibody variable light chain region comprising SEQ ID NO:71.64

56. The use of Claim 55, wherein the Cadherin-1 1-mediated disorder is an inflammatory disorder.

57. The use of Claim 56, wherein the inflammatory disorder is an inflammatory joint disorder.

58. The use of Claim 57, wherein the inflammatory joint disorder is rheumatoid arthritis.

59. The use of Claim 55, wherein the Cadherin-11-mediated disorder is fibrosis.

60. The use of Claim 55, wherein the Cadherin-1 1-mediated disorder is cancer.

61. Use of a humanized antibody in the manufacture of a medicament for the treatment of a Cadherin-11-mediated disorder in a mammalian subject, wherein the antibody specifically binds an EC 1 domain of a mammalian Cadherin-11 protein, comprises an antibody variable heavy chain region comprising SEQ ID NO:69 and an antibody variable light chain region comprising SEQ ID NO:71, and antagonizes said mammalian Cadherin-11 protein.

metalloproteinase in cells that express said mammalian Cadherin-1 1 protein in one or more joints of said subject.

53. The antibody of claim 41, wherein the antibody inhibits induction of expression or activity of a cytokine or growth factor selected from the group consisting of a IL-6, IL-8, RANKL and TRANCE in cells that express said mammalian Cadherin-1 1 protein in one or more joints of said subject.

54. The antibody of Claim 41, for use in the treatment of a Caherin-11-mediated disorder in a mammalian subject, wherein the antibody is administered to said subject in combination with at least one agent selected from the group consisting of a disease-modifying anti-rheumatic drug and an anti-inflammatory agent.

55. Use of a humanized antibody for the treatment of a Cadherin-11-mediated disorder in a mammalian subject in need thereof, wherein the antibody specifically binds an EC1 domain of a mammalian Cadherin-11 protein and comprises an antibody variable heavy chain region comprising SEQ ID NO:69 and an antibody variable light chain region comprising SEQ ID NO.:71.

56. The use of Claim 55, wherein the Cadherin-1 1-mediated disorder is an inflammatory disorder.

57. The use of Claim 56, wherein the inflammatory disorder is an inflammatory joint disorder.

58. The use of Claim 57, wherein the inflammatory joint disorder is rheumatoid arthritis.

59. The use of Claim 55, wherein the Cadherin-11-mediated disorder is fibrosis.

60. The use of Claim 55, wherein the Cadherin-1 1-mediated disorder is cancer.

61. Use of a humanized antibody in the manufacture of a medicament for the treatment of a Cadherin-11-mediated disorder in a mammalian subject, wherein the antibody specifically binds an EC 1 domain of a mammalian Cadherin-11 protein, comprises an antibody variable heavy chain region comprising SEQ ID NO:69 and an antibody variable light chain region comprising SEQ ID NO:71, and antagonizes said mammalian Cadherin-11 protein.